Chemotherapy in the treatment of malignant gliomas

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737140.6.5.755PMID 16759165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.

  2006cited by this paper
• Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

  2006cited by this paper
• High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.

  2006cited by this paper
• A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

  2006cited by this paper
• Intensity modulated radiotherapy in high grade gliomas: Clinical and dosimetric results.

  2006cited by this paper
• Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

  2006cited by this paper
• Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08)

  2006cited by this paper
• First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma

  2005cited by this paper
• Locoregional therapies for glioma.

  2005cited by this paper
• Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study

  2005cited by this paper
• Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

  2005cited by this paper
• Salvage temozolomide for prior temozolomide responders

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison.

  2005cited by this paper
• Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

  2005cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

  2005cited by this paper
• Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

  2005cited by this paper
• Targeted molecular therapy of malignant gliomas

  2005cited by this paper
• Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.

  2005cited by this paper
• Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01

  2005cited by this paper
• The sounds of silence: sexuality information for cancer patients.

  2005cited by this paper
• Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) phase II study

  2005cited by this paper
• A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients

  2005cited by this paper
• Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

  2005cited by this paper
• Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial.

  2004cited by this paper
• Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.

  2004cited by this paper
• Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

  2004cited by this paper
• Temozolomide in Combination With Irinotecan for Treatment of Recurrent Malignant Glioma

  2004cited by this paper
• Water intake and cancer prevention.

  2004cited by this paper
• Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme

  2004cited by this paper
• 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme.

  2004cited by this paper
• Phase II trial of gefitinib in recurrent glioblastoma.

  2004cited by this paper
• Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy.

  2004cited by this paper
• Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma.

  2004cited by this paper
• Thalidomide as an Anti-angiogenic Agent in Relapsed Gliomas

  2004cited by this paper
• Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

  2004cited by this paper
• NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas.

  2004cited by this paper
• Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

  2004cited by this paper
• Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

  2004cited by this paper
• Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

  2004cited by this paper
• Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.

  2004cited by this paper
• Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results.

  2004cited by this paper
• Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study.

  2004cited by this paper
• Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.

  2004cited by this paper
• A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs.

  2004cited by this paper
• An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02.

  2004cited by this paper
• Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

  2004cited by this paper
• Appetite and cancer-associated anorexia: a review.

  2004cited by this paper
• A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).

  2004cited by this paper
• Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results.

  2004cited by this paper
• Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen

  2003cited by this paper
• Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

  2003cited by this paper
• Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

  2003cited by this paper
• Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.

  2003cited by this paper
• A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

  2003cited by this paper
• Resection and prognosis.

  2003cited by this paper
• Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

  2003cited by this paper
• High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma

  2003cited by this paper
• Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.

  2003cited by this paper
• Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.

  2003cited by this paper
• Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

  2003cited by this paper
• Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.

  2002cited by this paper
• The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine

  2002cited by this paper
• Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

  2002cited by this paper
• Salvage Chemotherapy with CPT-11 for Recurrent Oligodendrogliomas

  2002cited by this paper
• The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.

  2002cited by this paper
• A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.

  2002cited by this paper
• Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

  2002cited by this paper
• Importance of hypoxia in the biology and treatment of brain tumors.

  2002cited by this paper
• Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme

  2001cited by this paper
• Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

  2001cited by this paper
• Temozolomide chemotherapy in recurrent oligodendroglioma

  2001cited by this paper
• A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

  2001cited by this paper
• Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

  2001cited by this paper
• Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial.

  2001cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.

  2000cited by this paper
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

  2000cited by this paper
• Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

  2000cited by this paper
• Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.

  1999cited by this paper
• Irinotecan therapy in adults with recurrent or progressive malignant glioma.

  1999cited by this paper
• Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

  1999cited by this paper
• Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas.

  1999cited by this paper
• Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study.

  1999cited by this paper
• Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.

  1999cited by this paper
• Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

  1999cited by this paper
• Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

  1998cited by this paper
• Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

  1998cited by this paper
• Phase I trial of temozolomide using an extended continuous oral schedule.

  1998cited by this paper
• DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

  1998cited by this paper
• Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium.

  1997cited by this paper
• Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial.

  1996cited by this paper
• Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.

  1996cited by this paper
• Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.

  1996cited by this paper
• Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma

  1996cited by this paper
• Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen.

  1996cited by this paper
• Salvage chemotherapy for oligodendroglioma.

  1996cited by this paper

• Nanoparticles Coated with Brain Microvascular Endothelial Cell Membranes can Target and Cross the Blood-Brain Barrier to Deliver Drugs to Brain Tumors.

  2024cites this paper
• Unveiling the Pharmacological Role of Human Deubiquitinating Enzymes in Temozolomide Response of Glioblastoma Cells

  2024cites this paper
• Inflammatory responsive neutrophil-like membrane-based drug delivery system for post-surgical glioblastoma therapy.

  2023cites this paper
• Neutrophil membrane-based nanotherapeutics: Propitious paradigm shift in the management of cancer.

  2023cites this paper
• Usage of Nanoparticles to Alter Neutrophils' Function for Therapy.

  2022cites this paper
• Neutrophil mediated drug delivery for targeted glioblastoma therapy: A comprehensive review.

  2022cites this paper
• Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery

  2021cites this paper
• Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood–brain barrier disruption: where are we now, and where we are going

  2020cites this paper
• Advances in endovascular neuro-oncology: endovascular selective intra-arterial (ESIA) infusion of targeted biologic therapy for brain tumors

  2019cites this paper
• Severe Traumatic Brain Injury.

  2018cites this paper
• Neutrophil-Guided Drug Delivery for Targeting Residual Glioma Cells.

  2018cites this paper
• Long noncoding RNA LINC01426 promotes glioma progression through PI3K/AKT signaling pathway and serves as a prognostic biomarker.

  2018cites this paper
• Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence.

  2017cites this paper
• Neutrophil-Guided Drug Delivery for Targeting Residual Glioma Cells

  2017cites this paper
• Endovascular therapies for malignant gliomas: Challenges and the future.

  2016cites this paper
• Fractional kinetics under external forcing

  2015cites this paper
• Fractional kinetics under external forcing

  2014cites this paper
• Drugs for Primary Brain Tumors: An Update

  2014cites this paper
• Toward Intracellular Targeted Delivery of Cancer Therapeutics

  2012cites this paper
• Rehabilitation in primary and metastatic brain tumours

  2008cites this paper
• Identifying candidate genes involved in brain tumor formation

  2008cites this paper
• Identifying candidate genes involved in brain tumor formation

  2008cites this paper
• Rehabilitation in primary and metastatic brain tumours Impact of functional outcomes on survival

  2008cites this paper
• PK 11195 differentially affects cell survival in human wild‐type and 18 kDa translocator protein‐silenced ADF astrocytoma cells

  2008cites this paper
• Screening for Candidate Brain Tumor Genes : Identifying Genes that Cooperate with Platelet-Derived Growth Factor in Glioma Development and Progression

  2006cites this paper
• IMSBP, une protéine identifiée comme une cible de la S100B, impliquée dans la distribution subcellulaire des mitochondries.

  2006cites this paper